The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment.
Lambertus P van den HeuvelNicole C A J van de KarCaroline DuineveldAndrei SarleaThea J A M van der VeldenWilhelmus T B LiebrandSanne van KraaijCamilla SchjalmRomy BouwmeesterJack F M WetzelsTom E MollnesElena B VolokhinaPublished in: Cellular & molecular immunology (2020)
Keyphrases